AOD-9604 and Tirzepatide Together: What Is Known
AOD-9604 and Tirzepatide taken together: what each one is, how each is regulated, and what is known about combining them.
Timing, interactions and safety
Evidence for the combination
No studies tested these together (PubMed search: 0 results, 2 Oct 2026).
Side by side
Showing 11 of 13 fields where the two differ. Category, PCAC vote, Jul 2026 are the same or both unknown.
| Field | AOD-9604 | Tirzepatide |
|---|---|---|
| Class | HGH fragment analog | GLP-1 / GIP dual agonist |
| Also called | AOD | tirz, tirze, Mounjaro, Zepbound |
| Category | GLP-1 & metabolic | GLP-1 & metabolic |
| FDA status | Not FDA approved · research chemical | FDA approved (Mounjaro, Zepbound) |
| PCAC vote, Jul 2026 | Not on the Jul 2026 agenda | Not on the Jul 2026 agenda |
| WADA | Prohibited by WADA (S2.2.3)AOD-9604 is named as a growth hormone fragment in S2.2.3, prohibited at all times. | Not on the WADA Prohibited ListGLP-1 and GIP agonists are not named anywhere on the 2026 list. This one is an approved medicine, so the catch-all S0 (which only covers drugs with no approval anywhere) does not apply to it. |
| Anti-doping detection |
| None reportedanti-doping literature, as of 2 Oct 2026 |
| Half-life | No published half-life foundPubMed search, 11 Oct 2026 | approximately 5 dayssubcutaneous · FDA label (Mounjaro) |
| Evidence strength | Animal evidence, 2 of 4Strongest: Annals of clinical and laboratory science 2015, PMID 26275694 | Human RCT evidence, 4 of 4Strongest: Arthritis & rheumatology 2026, PMID 41903163 |
| Human studies we summarised | 0 human (0 randomized or controlled) of 4 summarised | 24 human (22 randomized or controlled) of 30 summarised |
| Typical study doses |
|
|
| Vial sizes sold | 2 mg, 5 mg, 10 mg | 5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 120 mg |
| Named in FDA warning letters, 2026 | Not in the letters we track | Yes (24 Aug 2026; 31 Mar 2026) |
What each has been tested for
AOD-9604 weight data come from rodents: in a rat study, 19 days of oral AOD9604 cut body-weight gain by more than half versus controls.[7]
In obese mice, chronic AOD treatment reduced weight gain and was tied to fat oxidation and glycerol release, again an animal result.[16]
Tirzepatide has randomized human weight data: in SURMOUNT-5 it beat semaglutide head to head at week 72.[12]
Together
The dataset's PubMed search for this pair returned 0 records.
Calculated from pubmed query ("AOD-9604"[tiab] OR AOD9604[tiab]) AND (tirzepatide[tiab] OR Mounjaro[tiab] OR Zepbound[tiab] OR LY3298176[tiab]); search date 2026-10-02; records returned 0; records classed as study of the pair 0. Formula: Counts copied from the combinations dataset (web/src/data/combinations.json, key aod-9604__tirzepatide); no arithmetic applied.
On the approved side, the Zepbound label says the drug delays gastric emptying.[17]
What the approved side warns about
Tirzepatide carries a boxed warning from rodent studies: it caused thyroid C-cell tumours in rats, and the human relevance is not determined.[17]
Where each stands
AOD-9604 has no FDA-approved product: the Drugs@FDA lookup for it returned no match.[18]
WADA's prohibited list names AOD-9604 as an example of a growth hormone fragment.[4]
Drugs@FDA lists tirzepatide as Mounjaro, a prescription product.[19]
Common questions
Can you take AOD-9604 with tirzepatide?
No study of the pair is cited here. The Zepbound label says tirzepatide delays gastric emptying.[17]
AOD 9604 vs tirzepatide: how do they compare on weight?
AOD-9604's weight data cited here are from rodents: in rats, 19 days of oral AOD9604 cut body-weight gain by over 50%. Tirzepatide has randomized human trial data.[7]
Sources
- 1FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
- 2FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks listFDA · 2026fda.govAccessed 2 Oct 2026
- 3Seven FDA warning letters to online sellers of GLP-1 productsFDA warning letter (Gram Peptides; 1 of 7) · 2026fda.govAccessed 2 Oct 2026
- 4World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 5Detection and in vitro metabolism of AOD9604.Drug testing and analysis · 2015PMID 25208511Accessed 2 Oct 2026
- 6Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model.Annals of clinical and laboratory science · 2015PMID 26275694Accessed 2 Oct 2026
- 7Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone.Hormone research · 2000PMID 11146367Accessed 2 Oct 2026
- 8PubMed search: AOD9604[tiab] OR "AOD-9604"[tiab] OR "AOD 9604"[tiab] (22 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 9These highlights do not include all the information needed to use MOUNJARO safely and effectively. See full prescribing information for MOUNJARO. MOUNJARO ® (tirzepatide) Injection, for subcutaneous uFDA label (Mounjaro), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 10Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial.Arthritis & rheumatology (Hoboken, N.J.) · 2026PMID 41903163Accessed 2 Oct 2026
- 11Psychiatric Safety of Tirzepatide in People With Obesity and No Known Major Psychopathology: A Post Hoc Analysis of SURMOUNT.Obesity (Silver Spring, Md.) · 2026PMID 41537305Accessed 2 Oct 2026
- 12Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.The New England journal of medicine · 2025PMID 40353578Accessed 2 Oct 2026
- 13PubMed search: ("AOD-9604"[tiab] OR AOD9604[tiab]) AND (tirzepatide[tiab] OR Mounjaro[tiab] OR Zepbound[tiab] OR LY3298176[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 14Tirzepatide Once Weekly for the Treatment of Obesity.The New England journal of medicine · 2022PMID 35658024Accessed 2 Oct 2026
- 15PubMed search: (AOD9604[tiab] OR "AOD-9604"[tiab] OR "AOD 9604"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (6 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 16Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment.International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity · 2001PMID 11673763Accessed 2 Oct 2026
- 17ZEPBOUND prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 18Drugs@FDA (openFDA) search: active ingredient "AOD-9604"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
- 19Drugs@FDA (openFDA) search: active ingredient "tirzepatide"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
Found an error? Report a correction.